Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Liabilities and Shareholders Equity came in at $311.6 million in Q1 2026, up 37.21% year-on-year from $227.1 million in Q1 2025, and up 5.54% quarter-over-quarter from $295.2 million in Q4 2025.
Oculis Holding AG (OCS) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Oculis Holding AG's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $311.6 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 37.21% year-over-year to $311.6 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 56.29% increase from a year earlier, with the FY2025 full-year figure at $284.6 million, up 108.03% from the prior year.
- Liabilities and Shareholders Equity climbed to $311.6 million in Q1 2026 per OCS's latest filing, from $295.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $311.6 million in Q1 2026 and bottomed at $38.5 million in Q4 2022.
- The 5-year median for Liabilities and Shareholders Equity is $150.0 million (2023), against an average of $175.0 million.
- Across the five-year window, Liabilities and Shareholders Equity sank 38.89% in 2022 and soared 235.12% in 2023, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $38.5 million in 2022, then surged by 235.12% to $128.9 million in 2023, then increased by 6.57% to $137.4 million in 2024, then surged by 114.89% to $295.2 million in 2025, then climbed by 5.54% to $311.6 million in 2026.
- Per Business Quant, the three latest OCS Liabilities and Shareholders Equity figures stand at $311.6 million (Q1 2026), $295.2 million (Q4 2025), and $209.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 311.58 Mn |
| Dec 31, 2025 | 295.23 Mn |
| Sep 30, 2025 | 209.81 Mn |
| Jun 30, 2025 | 219.38 Mn |
| Mar 31, 2025 | 227.09 Mn |
| Dec 31, 2024 | 137.39 Mn |
| Sep 30, 2024 | 144.98 Mn |
| Jun 30, 2024 | 153.41 Mn |
| Mar 31, 2024 | 113.09 Mn |
| Dec 31, 2023 | 128.92 Mn |
| Sep 30, 2023 | 145.98 Mn |
| Jun 30, 2023 | 149.97 Mn |
| Dec 31, 2022 | 38.47 Mn |
| Dec 31, 2021 | 62.95 Mn |